Benitec Biopharma (BNTC) Liabilities and Shareholders Equity (2019 - 2025)
Historic Liabilities and Shareholders Equity for Benitec Biopharma (BNTC) over the last 7 years, with Q1 2025 value amounting to $105.2 million.
- Benitec Biopharma's Liabilities and Shareholders Equity rose 60144.01% to $105.2 million in Q1 2025 from the same period last year, while for Jun 2025 it was $253.1 million, marking a year-over-year increase of 11887.38%. This contributed to the annual value of $52.2 million for FY2024, which is 106957.89% up from last year.
- Per Benitec Biopharma's latest filing, its Liabilities and Shareholders Equity stood at $105.2 million for Q1 2025, which was up 60144.01% from $79.1 million recorded in Q4 2024.
- Benitec Biopharma's 5-year Liabilities and Shareholders Equity high stood at $105.2 million for Q1 2025, and its period low was $4.5 million during Q2 2023.
- In the last 5 years, Benitec Biopharma's Liabilities and Shareholders Equity had a median value of $17.8 million in 2021 and averaged $29.1 million.
- As far as peak fluctuations go, Benitec Biopharma's Liabilities and Shareholders Equity crashed by 7206.14% in 2022, and later surged by 106957.89% in 2024.
- Benitec Biopharma's Liabilities and Shareholders Equity (Quarter) stood at $14.0 million in 2021, then decreased by 15.05% to $11.9 million in 2022, then soared by 79.36% to $21.4 million in 2023, then skyrocketed by 270.29% to $79.1 million in 2024, then skyrocketed by 33.06% to $105.2 million in 2025.
- Its Liabilities and Shareholders Equity stands at $105.2 million for Q1 2025, versus $79.1 million for Q4 2024 and $68.8 million for Q3 2024.